Genix Pharmaceuticals Corp
XTSX:GENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 5-Year Average (0.9), the stock would be worth CA$-0.02 (200% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.9 | CA$0.02 |
0%
|
| 5-Year Average | 0.9 | CA$-0.02 |
-200%
|
| Industry Average | 2.9 | CA$-0.07 |
-442%
|
| Country Average | 2.7 | CA$-0.06 |
-408%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Genix Pharmaceuticals Corp
XTSX:GENX
|
1.2m CAD | -0.9 | -3.7 | |
| FR |
|
L'Oreal SA
PAR:OR
|
201.5B EUR | 5.8 | 32.9 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
93.4B GBP | 6.9 | 11.3 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.6T INR | 11.2 | 37.6 | |
| UK |
|
HALEON PLC
LSE:HLN
|
31.6B GBP | 1.9 | 19 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
28.1B USD | 7 | -158.1 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
15.8B EUR | 1.8 | 16.8 | |
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY | 2.5 | 22.2 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.2T INR | 9.6 | 64.1 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | -10 713 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
815.9B INR | 7.3 | 43.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
Genix Pharmaceuticals Corp
Glance View
Genix Pharmaceuticals Corp. engages in the the research, development, manufacture, licensing and sales of novel and innovative healthcare products, particularly proprietary over the counter nutraceuticals and generic pharmaceuticals. The company is headquartered in Vancouver, British Columbia. The firm focused on developing and licensing novels and products for sales through retail outlets and well as direct to consumers and e-commerce platforms. The firm holds licensing agreement for a range of products, including 30 Ophthalmic drugs, Sucanon, Renochlor, Flu-X, and Levothyroxine sodium (generic Synthroid). Flu-X anti-viral spray is an herbal, oral, anti-viral, anti-flu and anti-cold virus spray. Renochlor is an aid in the restoration of kidney health and kidney function. Sucanon is a natural substitute for prescription pharmaceuticals for non-insulin dependent diabetes patients.
